Managing Director, Takeda UK

Jon was appointed in January 2019 as the Managing Director of Takeda UK, following the global acquisition of Shire by Takeda. Jon is now leading Takeda’s significantly expanded presence in the UK & Ireland and is also responsible for the integration of the two legacy organisations. Previously, Jon had led the legacy Takeda UK & Ireland operation as Managing Director since May 2018.

Takeda is 238 years old, with a presence in approximately 80 countries, and expertise across rare disease, oncology, gastroenterology, neuroscience and diabetes. The Takeda-Shire combination means that Takeda is the largest Japanese biopharmaceutical company, and is expected to be a top 10 company – globally and in the UK – in the next few years.

Takeda continues to significantly invest in the UK, recently announcing a multi-million dollar investment in Cambridge biotech, Crescendo. Takeda also partners with UK stakeholders in initiatives such as our Commission to End the Diagnostic Odyssey for Children with a Rare Disease.

Jon joined Takeda in 2009 as a Strategic Marketing Director. He went on to become Business Unit Director for Specialist Medicines, before being appointed to Business Unit Director, Oncology.

Jon is committed to enhancing the reputation of the whole bio-pharmaceutical sector, demonstrated by his recent appearance before the All-Party Parliamentary Group on Access to Medicines, and his involvement in the Japanese Pharmaceutical Group where he is Vice-Chair.

Before joining Takeda, Jon worked for MSD and Servier.

Jon has a strong academic background in pharmacy, gaining his PhD from the University of Nottingham and he remains on the GPhC register.


17 November 2020